Freya Pharma Solutions appoints Nicole Hijnen as President of the Board, overseeing the company's upcoming clinical development program with Lybrido against FSIAD

AMSTERDAM, Feb. 2, 2023 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Nicole Hijnen, PhD (picture below) as President of Freya's Board as per January 2023. Dr. Hijnen is a health scientist who held a variety of senior management positions within Philips Healthtech, most recently as Director - Business Leader Connected Care Benelux. Her appointment comes in a year where Freya is rolling out its final clinical development program, starting with the confirmatory ALETTA clinical trial with Lybrido in premenopausal women with acquired FSIAD.

Marcel Wijma, CEO at Freya Pharma Solutions said:

"We are very pleased to have Nicole join Freya as President of our Board as we are on the brink of commencing our confirmatory clinical trial with our promising compound Lybrido against FSIAD. She brings exactly the right blend of academic and operational healthtech experience to help guide Freya to the next phase. With her deep knowledge of evolving FemTech science and technology, as well as her views on galvanizing an impassioned patient community, Nicole possesses all the skills to help propel our vision - addressing the urgent unmet medical need of women worldwide suffering from FSIAD."

In addition to bringing a wealth of experience from the healthtech industry at Philips, Dr. Hijnen has held a number of senior management and scientific positions worldwide. She obtained vast commercialization experience in the medical device industry and has a deep understanding of the EU and US markets. Within Philips she brought new medical devices to the US market among others, being responsible for end-to-end design, FDA approval, and sales, including claim strategy and setup of sales channels.

Dr. Hijnen obtained her MSc in Biomedical Engineering at TU - Eindhoven and her PhD in magnetic resonance-guided high intensity focused ultrasound for non-invasive thermal cancer therapy at TU - Eindhoven and Philips. Currently, she is a non-executive board member of the medical company SyncVR Medical. She is also an active investor in food and healthcare companies and participates in Arches Capital in Amsterdam, a group of business angels bridging the gap between Venture Capital companies (VCs) and business angels by connecting knowledge with capital.